Get started
Author

Karolien Vekens

Observed names: K Vekens, K. VEKENS, K. Vekens, KAROLIEN VEKENS, Vekens, Karolien
ORCID: 0000-0002-0088-1704
Observed ORCID: 0000-0002-0088-1704
OpenAlex ID: A5028475004
The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression
2021 · Karolien Vekens, Hendrik Everaert, et al. · Clinical Lung Cancer · 27
Primary Antimicrobial Resistance Ofhelicobacter Pyloriin Belgium
2013 · K Vekens, S Vandebosch, et al. · Acta Clinica Belgica · 15
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors
2024 · Manon Vounckx, Jens Tijtgat, et al. · Cancer Immunology Immunotherapy · 13
PDF
Features of post-obstructive pneumonia in advanced lung cancer patients, a large retrospective cohort
2022 · Marco Moretti, Shauni Wellekens, et al. · Scandinavian Journal of Infectious Diseases · 8
Lung cancer in a CF patient: combination of bad luck or is there more to say?
2020 · K Vekens, S Vincken, et al. · Acta Clinica Belgica · 8
Pulmonary function changes following helical tomotherapy in patients with inoperable, locally advanced non-small cell lung cancer
2019 · K. Vekens, S. Verbanck, et al. · Strahlentherapie und Onkologie · 6
Recurrence Risk and Its Impact on Current Treatment Strategies in Early and Locally Advanced NSCLC
2024 · CHARLOTTE TEGENBOSCH, KAROLIEN VEKENS · Anticancer Research · 3
A woman and her breathtaking jewelry
2020 · Dimitri Stylemans, Karolien Vekens, et al. · Acta Clinica Belgica · 2
Real world (RW) efficacy and toxicity of Ipilimumab (ipi)/Nivolumab(nivo) plus chemotherapy for older patients (pts) with PD-L1 negative, advanced non-small cell lung cancer (aNSCLC)
2025 · L. Decoster, E. Ravoet, et al. · Journal of Geriatric Oncology
Early neutrophil-to-lymphocyte ratio changes may act as predictors of response to immune checkpoint inhibitors in non-small-cell lung cancer
2025 · Karolien Vekens, Charlotte Dethier, et al. · Academia oncology.
48P: Real-world evaluation of ipilimumab (Ipi)/nivolumab (Nivo) in combination with two cycles of chemotherapy in patients (pts) with programmed death-ligand (PD-L1) negative advanced non-small cell lung cancer (aNSCLC): Interim results of the RW-9LA study
2025 · L. Decoster, S. Vande Kerckhove, et al. · Journal of Thoracic Oncology
PDF
Prediction of post‐operative lung physiology revisited
2024 · Sylvia Verbanck, Karolien Vekens, et al. · Respirology
PDF
Late Breaking Abstract - Functional prediction of post-operative lung physiology should really include diffusing capacity.
2023 · Sylvia Verbanck, Karolien Vekens, et al. · Transplantation
1096P Identifying predictive biomarkers for long term response on immunotherapy in non-small cell lung cancer (NSCLC)
2022 · L. Decoster, S. Nazari, et al. · Annals of Oncology
Features of Post-obstructive Pneumonia in Advanced Lung Cancer Patients: a Large Retrospective Cohort
2022 · M. MORETTI, S. WELLEKENS, et al. · CHEST Journal
PDF
Works count: 16
Citation count: 82
H-index: 6
I10-index: 3
Year
Topic
Type